Financial Performance - Company reported a total revenue of 2.845 billion yuan for the first half of 2025, a decrease of 6.62% year-on-year [1] - Net profit for the same period was 107 million yuan, down 6.69% year-on-year [1] - In Q2 2025, total revenue was 1.404 billion yuan, a decline of 4.12% year-on-year, while net profit increased by 17.66% to 65.95 million yuan [1] Profitability Metrics - Gross margin stood at 17.29%, a decrease of 3.42% compared to the previous year [1] - Net margin improved slightly to 5.01%, an increase of 0.72% year-on-year [1] - Total selling, administrative, and financial expenses amounted to 312 million yuan, accounting for 10.95% of revenue, down 3.01% year-on-year [1] Cash Flow and Assets - Operating cash flow per share increased by 25.52% to 0.12 yuan [1] - Cash and cash equivalents were reported at 666.6 million yuan, a significant increase of 36.79% [1] - Accounts receivable decreased to 2.481 billion yuan, down 11.08% year-on-year [1] Historical Performance and Business Model - Company has a historical median ROIC of 4.25%, indicating weak capital returns [3] - The net profit margin for the previous year was 2.58%, suggesting low added value in products or services [3] - The business model relies heavily on marketing-driven performance, necessitating further investigation into the underlying drivers [3] Accounts Receivable Concerns - Accounts receivable to profit ratio reached 2447.31%, raising concerns about the company's receivables management [3]

Company Overview - Xinfang Pharmaceutical (SZ 002390) announced its 8th meeting of the 9th Board of Directors held on August 28, 2025, in Guiyang, Guizhou Province, focusing on the revision of the "Audit Committee Work Rules" [1] Financial Performance - For the first half of 2025, Xinfang Pharmaceutical's revenue composition was as follows: pharmaceutical distribution accounted for 75.12%, medical services 27.8%, pharmaceutical manufacturing 17.27%, other industries 0.03%, and consolidation adjustments at -20.23% [1]

智通财经APP讯，信邦制药(002390.SZ)发布2025年半年度报告，该公司营业收入为28.45亿元，同比减少6.62%。归属于上市公司股东的净利润为1.07亿元， 同比减少6.69%。归属于上市公司股东的扣除非经常性损益的净利润为1.07亿元，同比减少7.16%。基本每股收益为0.0565元。 ...

Core Viewpoint - Xinfeng Pharmaceutical (002390.SZ) reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first half of 2025 was 2.845 billion yuan, a year-on-year decrease of 6.62% [1] - The net profit attributable to shareholders was 107 million yuan, down 6.69% compared to the previous year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was also 107 million yuan, reflecting a decrease of 7.16% year-on-year [1] - Basic earnings per share were reported at 0.0565 yuan [1]

Section 1 Important Notes, Table of Contents, and Definitions This section provides essential preliminary information, including management's assurance, the report's structure, and definitions of key terms for clarity [Important Notes](index=2&type=section&id=Important%20Notes) The board and management assure the report's accuracy, with forward-looking statements not being commitments, and a cash dividend of 0.30 yuan per 10 shares proposed - The company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report, with no false records, misleading statements, or major omissions[4](index=4&type=chunk) - Company head An Ji, chief accounting officer Xiao Yaya, and head of accounting department Liao Juan declare the financial report in this semi-annual report is true, accurate, and complete[4](index=4&type=chunk) 2025 Semi-Annual Profit Distribution Plan | Indicator | Content | | :--- | :--- | | **Distribution Base** | Total share capital of 1,896,406,328 shares, after deducting 47,445,540 repurchased shares from the company's total share capital of 1,943,851,868 shares | | **Distribution Plan** | Cash dividend of **0.30 yuan** (including tax) per 10 shares to all shareholders | | **Bonus Shares** | 0 shares (including tax) | | **Capital Reserve to Share Capital Conversion** | No capital reserve to share capital conversion | [Table of Contents](index=3&type=section&id=Table%20of%20Contents) The report's clear structure covers key sections like company profile, financial indicators, management discussion, and lists reference documents - The report's main chapters include: Section 1 Important Notes, Table of Contents, and Definitions; Section 2 Company Profile and Key Financial Indicators; Section 3 Management Discussion and Analysis; Section 9 Other Submitted Data[7](index=7&type=chunk) - Reference documents include: Financial statements signed and sealed by the legal representative, chief accounting officer, and head of accounting department; Originals of all company documents publicly disclosed during the reporting period and announcements; The company's 2025 semi-annual report signed by the chairman; Other relevant materials[9](index=9&type=chunk)[10](index=10&type=chunk)[11](index=11&type=chunk)[12](index=12&type=chunk) [Definitions](index=5&type=section&id=Definitions) This section defines key terms, including legal, regulatory, company, and pharmaceutical industry-specific terminology for clarity - The report defines laws and regulations such as the Company Law, Securities Law, China Securities Regulatory Commission, and Shenzhen Stock Exchange[14](index=14&type=chunk) - Detailed names of the company and its controlling/wholly-owned subsidiaries are listed, such as Guizhou Kekai Pharmaceutical Co., Ltd., Guizhou Xinbang Pharmaceutical Co., Ltd., and Guizhou Medical University Affiliated Cancer Hospital Co., Ltd[14](index=14&type=chunk)[15](index=15&type=chunk) - Pharmaceutical industry professional terms are explained, including Good Clinical Practice (GCP), Direct-to-Patient (DTP), Big Data-based Disease Diagnosis Payment (DIP), Diagnosis-Related Groups (DRG), etc[15](index=15&type=chunk) Section 2 Company Profile and Key Financial Indicators This section outlines the company's fundamental information and presents key accounting data and financial indicators, highlighting performance trends and asset-liability status [Company Profile](index=7&type=section&id=Company%20Profile) This section provides the company's basic information, such as stock details, name, and legal representative, confirming no changes in contact details Company Basic Information | Indicator | Content | | :--- | :--- | | **Stock Abbreviation** | Xinbang Pharmaceutical | | **Stock Code** | 002390 | | **Stock Listing Exchange** | Shenzhen Stock Exchange | | **Company Chinese Name** | Guizhou Xinbang Pharmaceutical Co., Ltd | | **Legal Representative** | An Ji | - The company's registered address, office address, website, and email address remained unchanged during the reporting period, as detailed in the 2024 annual report[18](index=18&type=chunk) [Key Accounting Data and Financial Indicators](index=7&type=section&id=Key%20Accounting%20Data%20and%20Financial%20Indicators) Operating revenue and net profit declined, impacting EPS and ROE, while total assets slightly decreased, net assets grew, and operating cash flow significantly increased 2025 Semi-Annual Key Financial Data Comparison | Indicator | Current Reporting Period (yuan) | Prior Year Period (yuan) | YoY Change | | :--- | :--- | :--- | :--- | | **Operating Revenue** | 2,845,025,271.68 | 3,046,569,827.96 | **-6.62%** | | **Net Profit Attributable to Listed Company Shareholders** | 107,196,832.89 | 114,879,289.31 | **-6.69%** | | **Net Profit Attributable to Listed Company Shareholders (Excluding Non-Recurring Gains/Losses)** | 106,629,463.12 | 114,851,463.77 | **-7.16%** | | **Net Cash Flow from Operating Activities** | 227,425,647.80 | 181,185,712.37 | **25.52%** | | **Basic Earnings Per Share (yuan/share)** | 0.0565 | 0.0602 | **-6.15%** | | **Diluted Earnings Per Share (yuan/share)** | 0.0565 | 0.0602 | **-6.15%** | | **Weighted Average Return on Net Assets** | 1.59% | 1.67% | **Decreased by 0.08 percentage points** | 2025 Semi-Annual End Asset and Liability Indicators Comparison | Indicator | End of Current Reporting Period (yuan) | End of Prior Year (yuan) | Change from End of Prior Year | | :--- | :--- | :--- | :--- | | **Total Assets** | 8,786,737,328.44 | 9,028,336,478.89 | **-2.68%** | | **Net Assets Attributable to Listed Company Shareholders** | 6,760,732,531.15 | 6,710,056,421.59 | **0.76%** | [Differences in Accounting Data under Domestic and International Accounting Standards](index=8&type=section&id=Differences%20in%20Accounting%20Data%20under%20Domestic%20and%20International%20Accounting%20Standards) The company reports no differences in net profit or net assets between domestic and international accounting standards during the period - The company's reporting period shows no differences in net profit and net assets between financial reports disclosed under International Accounting Standards and Chinese Accounting Standards[22](index=22&type=chunk) - The company's reporting period shows no differences in net profit and net assets between financial reports disclosed under overseas accounting standards and Chinese Accounting Standards[23](index=23&type=chunk) [Non-Recurring Gains and Losses Items and Amounts](index=8&type=section&id=Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) This section details non-recurring gains and losses, confirming no other such items and no reclassification of listed non-recurring items as recurring 2025 Semi-Annual Non-Recurring Gains and Losses Items and Amounts | Item | Amount (yuan) | | :--- | :--- | | Non-current asset disposal gains and losses | 95,696.33 | | Government grants recognized in current profit or loss | 227,425,647.80 | | Gains and losses from entrusted investments or asset management | 304,964.14 | | Other non-operating income and expenses apart from the above | -1,513,389.14 | | Less: Income tax impact | -36,044.03 | | Minority interest impact (after tax) | 15,504.25 | | **Total** | **567,369.77** | - The company has no other specific situations that meet the definition of non-recurring gains and losses[24](index=24&type=chunk) - The company has not reclassified any non-recurring gains and losses items listed in "Interpretive Announcement No. 1 for Information Disclosure by Companies Issuing Securities to the Public—Non-Recurring Gains and Losses" as recurring gains and losses[24](index=24&type=chunk) Section 3 Management Discussion and Analysis This section details the company's main businesses, core competencies, and operational performance, along with an analysis of assets, liabilities, investments, and significant risks [Main Businesses Engaged by the Company During the Reporting Period](index=9&type=section&id=Main%20Businesses%20Engaged%20by%20the%20Company%20During%20the%20Reporting%20Period) The company maintained its "healthcare service+" model, driven by an aging population, improved medical insurance, and strategic optimizations in medical services, distribution, and manufacturing - The company has formed a main business structure centered on medical services, supplemented by pharmaceutical distribution and traditional Chinese medicine manufacturing, establishing a "healthcare service+" platform operating model[26](index=26&type=chunk) - In medical services, the company owns **6 medical institutions**, including a tumor hospital, Baiyun Hospital, and Wudang Hospital, with over **4,500 beds**, forming a medical service network primarily focused on oncology and general hospital systems[29](index=29&type=chunk) - In pharmaceutical distribution, the company is a leading enterprise in Guizhou Province, holding provincial exclusive agency rights for numerous well-known domestic and international upstream suppliers, and has established a sales network covering major hospitals within the province[31](index=31&type=chunk) - In pharmaceutical manufacturing, the company possesses **11 national essential drug catalog varieties** and **23 national medical insurance catalog varieties**, with a traditional Chinese medicine decoction piece processing capacity of **6,000 tons/year**, and has developed **13 food-medicine homologous products** and **5 traditional Chinese medicine health products**[31](index=31&type=chunk)[32](index=32&type=chunk) - Performance drivers include the continuous growth of the healthcare market due to an aging population, rising resident incomes, and improved medical insurance system, as well as national policies promoting private medical institutions and increasing concentration in the pharmaceutical distribution industry[34](index=34&type=chunk) - Company-specific factors include "homogenized development, integrated management" in medical services to enhance operational quality, consolidation of geographical advantages and value-added supply chain services in pharmaceutical distribution, new growth points from centralized procurement of traditional Chinese medicine decoction pieces in pharmaceutical manufacturing, and accelerated development of health products[34](index=34&type=chunk)[35](index=35&type=chunk) [Analysis of Core Competencies](index=11&type=section&id=Analysis%20of%20Core%20Competencies) The company's core competencies stem from its integrated healthcare platform, flexible corporate mechanisms, and strong business advantages in medical services, pharmaceutical distribution, and manufacturing - The company has become a full-产业链 healthcare group integrating medical services, pharmaceutical distribution, and traditional Chinese medicine manufacturing, forming a "healthcare service+" platform operating model with advantages in resource sharing, strong risk resistance, high management efficiency, and low financing costs[36](index=36&type=chunk) - The flexible mechanism of a joint-stock enterprise provides competitive advantages in business expansion, decision-making efficiency, talent incentives, and cost control, facilitating the development of high-end diversified medical demands and synergistic business operations[37](index=37&type=chunk) - Medical service advantages include: owning **6 medical institutions** with over **4,500 beds**, with the tumor hospital being Guizhou Province's only **Grade A tertiary oncology specialist hospital**; adhering to synergistic development of medical care, teaching, and research, possessing a GCP institution, oncology research laboratory, and molecular pathology center; implementing an "integrated management, homogenized development" model; prioritizing medical quality and patient-centricity; building regional flagship hospitals and integrated traditional Chinese and Western medicine flagship hospitals; and leveraging informatization and new technologies to foster new business formats[38](index=38&type=chunk)[39](index=39&type=chunk)[40](index=40&type=chunk)[41](index=41&type=chunk)[42](index=42&type=chunk)[43](index=43&type=chunk) - Pharmaceutical distribution advantages include: consolidating its leading position in the province, with over **95% coverage** of hospitals above a certain grade; leveraging terminal advantages to highlight supply chain value; and refining and dynamizing management to enhance operational quality[43](index=43&type=chunk)[44](index=44&type=chunk) - Pharmaceutical manufacturing advantages include: mature proprietary Chinese medicine products with generally stable sales; reliable quality of traditional Chinese medicine decoction pieces, which have been selected for national centralized procurement; and clear origin, stable quality, and safety of health products[44](index=44&type=chunk)[45](index=45&type=chunk) [Analysis of Main Business](index=14&type=section&id=Analysis%20of%20Main%20Business) Overall revenue and net profit declined, with medical services slightly down, pharmaceutical distribution significantly down due to policy, and pharmaceutical manufacturing growing from decoction pieces and health products 2025 Semi-Annual Main Business Revenue and YoY Change | Business Segment | Operating Revenue (10,000 yuan) | YoY Change | | :--- | :--- | :--- | | **Medical Services** | 79,095.33 | **-1.89%** | | **Pharmaceutical Distribution** | 213,732.34 | **-12.10%** | | **Pharmaceutical Manufacturing** | 49,139.25 | **7.38%** | | **Total Operating Revenue** | 284,502.53 | **-6.62%** | | **Net Profit Attributable to Listed Company Shareholders** | 10,719.68 | **-6.69%** | | **Basic Earnings Per Share** | 0.0565 yuan/share | **-6.15%** | - Medical service business improved service quality and discipline construction by strengthening informatization, optimizing nursing services, innovating doctor-patient relationship management, and deepening cooperation with Jiangsu Provincial Hospital of Traditional Chinese Medicine[47](index=47&type=chunk) - Pharmaceutical distribution business actively responded to the impact of centralized procurement policies, strengthening collection management, supplier cooperation, inventory management, and promoting professional pharmacy services in pharmaceutical retail[48](index=48&type=chunk) - In pharmaceutical manufacturing, proprietary Chinese medicine sales were stable, non-centralized procurement of traditional Chinese medicine decoction pieces increased, centralized procurement business achieved sales in Shandong, Hunan, Fujian, and other provinces, and health product business accelerated R&D and marketing system construction[48](index=48&type=chunk) 2025 Semi-Annual Operating Revenue Composition (by Region) | Region | Operating Revenue (yuan) | Proportion of Operating Revenue | | :--- | :--- | :--- | | **Southwest** | 2,959,635,721.84 | **86.52%** | | **East China** | 396,076,195.97 | **11.58%** | | **North China** | 33,718,551.48 | **0.99%** | | **Central China** | 17,692,089.56 | **0.52%** | | **Northeast** | 5,619,208.81 | **0.16%** | | **South China** | 5,097,001.36 | **0.15%** | | **Northwest** | 2,798,750.71 | **0.08%** | [Analysis of Non-Core Business](index=16&type=section&id=Analysis%20of%20Non-Core%20Business) Non-core business activities included investment income from dividends and asset impairment primarily from bad debt provisions 2025 Semi-Annual Non-Core Business Profit and Loss | Item | Amount (yuan) | Explanation of Cause | Sustainability | | :--- | :--- | :--- | :--- | | **Investment Income** | 304,964.14 | Dividends from professional investment institutions | No | | **Asset Impairment** | -6,287,040.22 | Provision for bad debts | Yes | | **Non-Operating Income** | 368,044.83 | Donations received, write-off of unpayable amounts | No | | **Non-Operating Expenses** | 2,095,788.70 | Loss from disposal of non-current assets, donation expenses, etc | No | [Analysis of Assets and Liabilities](index=16&type=section&id=Analysis%20of%20Assets%20and%20Liabilities) Total and current assets decreased, non-current assets were stable, short-term debt and notes payable fell, long-term debt rose, and receivables financing increased 2025 Semi-Annual End Asset Composition Change | Item | End of Current Reporting Period (yuan) | Proportion of Total Assets | End of Prior Year (yuan) | Proportion of Total Assets | Change Rate | | :--- | :--- | :--- | :--- | :--- | :--- | | **Total Assets** | 8,786,737,328.44 | 100% | 9,028,336,478.89 | 100% | **-2.68%** | | **Cash and Cash Equivalents** | 998,531,222.17 | 11.36% | 1,015,515,313.40 | 11.25% | **-1.67%** | | **Accounts Receivable** | 2,481,121,499.98 | 28.24% | 2,534,340,405.01 | 28.07% | **-2.10%** | | **Inventories** | 957,708,052.36 | 10.90% | 1,060,430,088.41 | 11.75% | **-9.69%** | | **Fixed Assets** | 2,178,278,054.09 | 24.79% | 2,259,606,380.29 | 25.03% | **-3.60%** | | **Construction in Progress** | 176,615,457.23 | 2.01% | 145,022,006.06 | 1.61% | **21.79%** | 2025 Semi-Annual End Liability Composition Change | Item | Period-End Balance (yuan) | Proportion of Total Liabilities | Period-Beginning Balance (yuan) | Proportion of Total Liabilities | Change Rate | | :--- | :--- | :--- | :--- | :--- | :--- | | **Short-Term Borrowings** | 455,162,591.41 | 5.18% | 592,340,496.38 | 6.56% | **-23.15%** | | **Contract Liabilities** | 42,854,462.86 | 0.49% | 25,936,373.62 | 0.29% | **65.20%** | | **Long-Term Borrowings** | 245,700,000.00 | 2.80% | 160,000,000.00 | 1.77% | **53.56%** | - Other changes in "Receivables Financing" represent the net increase or decrease in bank acceptance bills and accounts receivable (for which the business model aims to both collect contractual cash flows and sell) from banks with high credit ratings[55](index=55&type=chunk) [Analysis of Investment Status](index=17&type=section&id=Analysis%20of%20Investment%20Status) No significant equity, securities, or derivative investments occurred, with a major hospital construction project 95% complete and no raised funds utilized - The company had no securities investments or derivative investments during the reporting period[58](index=58&type=chunk)[59](index=59&type=chunk) 2025 Semi-Annual Major Non-Equity Investment | Project Name | Investment Industry | Investment Method | Amount Invested in Current Period (yuan) | Cumulative Actual Investment at Period-End (yuan) | Project Progress | | :--- | :--- | :--- | :--- | :--- | :--- | | Guizhou Medical University Affiliated Baiyun Hospital Phase III Construction Project (Internal Medicine Inpatient Comprehensive Building) | Medical Services | Self-built | 43,125,331.01 | 173,821,691.16 | **95.00%** | - The company had no use of raised funds during the reporting period[60](index=60&type=chunk) [Significant Asset and Equity Sales](index=19&type=section&id=Significant%20Asset%20and%20Equity%20Sales) The company did not engage in any significant asset or equity sales during the reporting period - The company did not sell significant assets during the reporting period[62](index=62&type=chunk) - The company did not sell significant equity during the reporting period[63](index=63&type=chunk) [Analysis of Major Holding and Participating Companies](index=19&type=section&id=Analysis%20of%20Major%20Holding%20and%20Participating%20Companies) This section analyzes major subsidiaries, highlighting Guizhou Tongde, Guizhou Kekai, and Guizhou Medical University Affiliated Cancer Hospital's significant impact on net profit 2025 Semi-Annual Major Holding and Participating Companies Financial Data | Company Name | Main Business | Total Assets (yuan) | Net Assets (yuan) | Operating Revenue (yuan) | Net Profit (yuan) | | :--- | :--- | :--- | :--- | :--- | :--- | | Guizhou Tongde Pharmaceutical Co., Ltd | Processing and sales of traditional Chinese medicine decoction pieces | 933,533,624.89 | 375,597,447.68 | 341,364,596.39 | 100,164,744.27 | | Guizhou Kekai Pharmaceutical Co., Ltd | Pharmaceutical sales | 3,675,426,643.49 | 2,596,039,309.66 | 1,063,034,373.45 | 45,382,518.52 | | Guizhou Medical University Affiliated Cancer Hospital Co., Ltd | Medical services | 1,010,784,506.12 | 375,769,843.76 | 381,486,521.05 | 24,696,432.26 | - During the reporting period, Guizhou Daohe Real Estate Co., Ltd. was established, increasing the scope of consolidation[61](index=61&type=chunk) [Structured Entities Controlled by the Company](index=19&type=section&id=Structured%20Entities%20Controlled%20by%20the%20Company) The company did not control any structured entities during the reporting period - The company had no controlled structured entities during the reporting period[64](index=64&type=chunk) [Risks Faced by the Company and Countermeasures](index=19&type=section&id=Risks%20Faced%20by%20the%20Company%20and%20Countermeasures) The company faces diverse risks from policy, competition, costs, human resources, and operations, and will proactively adjust strategies for sustainable development - Industry risk: Deepening national medical reform, centralized volume-based procurement, DRG/DIP payment method reforms, and other policies lead to drug price reductions, threatening a decline in industry average profit margins[64](index=64&type=chunk) - Market competition risk: Release of health demand and increased market participation intensify competition[65](index=65&type=chunk) - Cost increase risk: Rising raw material prices, human resource costs, and fixed asset depreciation expenses may impact profitability[65](index=65&type=chunk) - Human resource risk: Increased business demands a greater need for various talents, posing risks of recruitment difficulties and existing personnel turnover[65](index=65&type=chunk) - Management risk: Expanding company scale and business scope present higher challenges for management integration capabilities[65](index=65&type=chunk) - Medical accident risk: Medical errors and accidents cannot be entirely avoided in clinical medical processes[66](index=66&type=chunk) - Accounts receivable risk: Expanding business scale leads to increased accounts receivable, and potential bad debts if major customers' financial conditions deteriorate[66](index=66&type=chunk) - Financial risk: Production and operations require substantial working capital investment, potentially exposing the company to credit risk, market risk, and liquidity risk[66](index=66&type=chunk) - Environmental risk: Increasing environmental protection investments may affect future profitability[66](index=66&type=chunk) - Countermeasures: The company will actively monitor and promptly adjust strategies as appropriate, implementing measures to strive for the timely and successful completion of operational goals and plans, ensuring high-quality sustainable development[67](index=67&type=chunk) [Implementation of Market Value Management System and Valuation Enhancement Plan](index=20&type=section&id=Implementation%20of%20Market%20Value%20Management%20System%20and%20Valuation%20Enhancement%20Plan) The company neither established a market value management system nor disclosed a valuation enhancement plan during the reporting period - The company did not establish a market value management system during the reporting period[68](index=68&type=chunk) - The company did not disclose a valuation enhancement plan during the reporting period[68](index=68&type=chunk) [Implementation of "Quality and Return Dual Improvement" Action Plan](index=20&type=section&id=Implementation%20of%20%E2%80%9CQuality%20and%20Return%20Dual%20Improvement%E2%80%9D%20Action%20Plan) The company did not disclose an announcement for the "Quality and Return Dual Improvement" action plan during the reporting period - The company did not disclose an announcement regarding the "Quality and Return Dual Improvement" action plan during the reporting period[69](index=69&type=chunk) Section 4 Corporate Governance, Environment, and Society This section covers corporate governance aspects, including changes in management, profit distribution, and disclosures related to environmental performance and social responsibility initiatives [Changes in Directors, Supervisors, and Senior Management](index=22&type=section&id=Changes%20in%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) No changes occurred in the company's directors, supervisors, or senior management during the reporting period - The company's directors, supervisors, and senior management experienced no changes during the reporting period, with details available in the 2024 annual report[71](index=71&type=chunk) [Profit Distribution and Capital Reserve to Share Capital Conversion for the Reporting Period](index=22&type=section&id=Profit%20Distribution%20and%20Capital%20Reserve%20to%20Share%20Capital%20Conversion%20for%20the%20Reporting%20Period) The 2025 semi-annual profit distribution plan proposes a 0.30 yuan (tax-inclusive) cash dividend per 10 shares, with no bonus shares or capital reserve conversion 2025 Semi-Annual Profit Distribution Plan | Indicator | Content | | :--- | :--- | | **Number of Bonus Shares per 10 Shares** | 0 shares | | **Dividend per 10 Shares (including tax)** | 0.30 yuan | | **Share Capital Base for Distribution Plan** | 1,896,406,328 shares | | **Cash Dividend Amount (including tax)** | 56,892,189.84 yuan | | **Proportion of Total Cash Dividend to Total Profit Distribution** | **100%** | - If the company's development stage is difficult to distinguish but has significant capital expenditure arrangements, the minimum proportion of cash dividends in the total profit distribution should reach **20%**[70](index=70&type=chunk) [Implementation of Company Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures](index=22&type=section&id=Implementation%20of%20Company%20Equity%20Incentive%20Plans%2C%20Employee%20Stock%20Ownership%20Plans%2C%20or%20Other%20Employee%20Incentive%20Measures) The company had no equity incentive, employee stock ownership, or other employee incentive plans or their implementation during the reporting period - The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures, nor their implementation, during the reporting period[72](index=72&type=chunk) [Environmental Information Disclosure](index=22&type=section&id=Environmental%20Information%20Disclosure) The company and its main subsidiaries are on the environmental information disclosure list, with a report query index provided - The listed company and its main subsidiaries are included in the list of enterprises required to disclose environmental information by law[73](index=73&type=chunk) - The query index for Guizhou Xinbang Pharmaceutical Co., Ltd.'s environmental information disclosure report has been provided[70](index=70&type=chunk) [Social Responsibility](index=22&type=section&id=Social%20Responsibility) In H1 2025, the company actively fulfilled social responsibilities through industrial and medical assistance, social welfare, and environmental protection, driving local economy and supporting healthcare - The company continued to deepen industrial support for economically disadvantaged regions, with its proprietary Chinese medicine and traditional Chinese medicine decoction piece production bases becoming local economic pillars, driving the upgrading of the local traditional Chinese medicine industry and increasing farmers' incomes[74](index=74&type=chunk) - In medical assistance, the company's hospitals conducted **277 large and medium-sized free clinics and health lectures**, providing free medical services to over **10,000 people**, and invested **1.1566 million yuan** to provide palliative care services to over **350 late-stage cancer patients**[74](index=74&type=chunk) - In social welfare, the company donated **800,000 yuan** to the Guizhou Medical University Education Development Foundation and the "Xiehe Class" special fund to support medical talent cultivation, and carried out activities such as visiting left-behind children, providing college entrance examination volunteer services, employment recommendations, and purchasing agricultural products[75](index=75&type=chunk) - In environmental protection, the company strictly implemented national environmental policies and regulations, strengthening energy conservation and emission reduction, "three wastes" treatment, energy efficiency optimization, and noise control technology upgrades, with no major environmental or social safety accidents occurring in the first half of the year[75](index=75&type=chunk) Section 5 Significant Matters This section addresses critical corporate events, including commitments, related party transactions, significant contracts, litigation, and other material disclosures [Commitments](index=24&type=section&id=Commitments) No commitments by the company, its controller, shareholders, or related parties were overdue or unfulfilled during the reporting period - During the reporting period, there were no commitments by the company's actual controller, shareholders, related parties, acquirers, or the company that were either fulfilled or overdue and unfulfilled by the end of the reporting period[78](index=78&type=chunk) [Non-Operating Fund Occupation by Controlling Shareholder and Other Related Parties](index=24&type=section&id=Non-Operating%20Fund%20Occupation%20by%20Controlling%20Shareholder%20and%20Other%20Related%20Parties) No non-operating funds were occupied by the controlling shareholder or related parties during the reporting period - During the reporting period, there was no non-operating occupation of funds by the controlling shareholder or other related parties of the listed company[79](index=79&type=chunk) [Irregular External Guarantees](index=24&type=section&id=Irregular%20External%20Guarantees) The company had no irregular external guarantees during the reporting period - The company had no irregular external guarantees during the reporting period[80](index=80&type=chunk) [Appointment and Dismissal of Accounting Firms](index=24&type=section&id=Appointment%20and%20Dismissal%20of%20Accounting%20Firms) The semi-annual financial report was unaudited, so no appointment or dismissal of accounting firms occurred - The company's semi-annual report was unaudited[81](index=81&type=chunk) [Board of Directors' and Supervisory Board's Explanation on "Non-Standard Audit Report"](index=24&type=section&id=Board%20of%20Directors%27%20and%20Supervisory%20Board%27s%20Explanation%20on%20%22Non-Standard%20Audit%20Report%22) No "non-standard audit report" was issued, so no explanation from the board or supervisory board is required - During the reporting period, the company did not receive a "non-standard audit report" from its accounting firm[82](index=82&type=chunk) [Board of Directors' Explanation on "Non-Standard Audit Report" from Previous Year](index=24&type=section&id=Board%20of%20Directors%27%20Explanation%20on%20%22Non-Standard%20Audit%20Report%22%20from%20Previous%20Year) No "non-standard audit report" from the previous year existed, so no board explanation is required - During the reporting period, there were no circumstances related to a "non-standard audit report" from the previous year[82](index=82&type=chunk) [Bankruptcy and Reorganization Matters](index=24&type=section&id=Bankruptcy%20and%20Reorganization%20Matters) The company had no bankruptcy or reorganization matters during the reporting period - The company did not experience any bankruptcy or reorganization matters during the reporting period[82](index=82&type=chunk) [Litigation Matters](index=24&type=section&id=Litigation%20Matters) No significant litigation or arbitration occurred; minor cases involved 152.517 million yuan as plaintiff and 10.3868 million yuan as defendant - The company had no significant litigation or arbitration matters during this reporting period[83](index=83&type=chunk) 2025 Semi-Annual Other Litigation Matters Summary | Litigation (Arbitration) Basic Situation | Amount Involved (10,000 yuan) | Provision for Liabilities Formed | Litigation (Arbitration) Progress | Adjudication Results and Impact | | :--- | :--- | :--- | :--- | :--- | | Summary of cases not meeting significant litigation/arbitration threshold (Plaintiff) | 15,251.7 | No | Adjudication stage | Adjudicated amount of **13,058.65 million yuan** | | Summary of cases not meeting significant litigation/arbitration threshold (Defendant) | 1,038.68 | No | Adjudication stage | Still under review, no significant impact | [Penalties and Rectification](index=25&type=section&id=Penalties%20and%20Rectification) The company had no penalties or rectification situations during the reporting period - The company had no penalties or rectification situations during the reporting period[85](index=85&type=chunk) [Integrity Status of the Company, its Controlling Shareholder, and Actual Controller](index=25&type=section&id=Integrity%20Status%20of%20the%20Company%2C%20its%20Controlling%20Shareholder%2C%20and%20Actual%20Controller) No integrity issues were reported for the company, its controlling shareholder, or actual controller during the period - During the reporting period, there were no issues regarding the integrity status of the company, its controlling shareholder, or actual controller[86](index=86&type=chunk) [Significant Related Party Transactions](index=25&type=section&id=Significant%20Related%20Party%20Transactions) No significant related party transactions occurred, including those related to operations, asset/equity deals, joint investments, or financial services with related financial companies - The company had no related party transactions related to daily operations during the reporting period[86](index=86&type=chunk) - The company had no related party transactions involving asset or equity acquisitions/disposals during the reporting period[87](index=87&type=chunk) - The company had no related party transactions involving joint external investments during the reporting period[88](index=88&type=chunk) - The company had no related party creditor-debtor relationships during the reporting period[89](index=89&type=chunk) - The company had no deposits, loans, credit lines, or other financial services with related financial companies during the reporting period[90](index=90&type=chunk) - The company's controlled financial companies had no deposits, loans, credit lines, or other financial services with related parties during the reporting period[91](index=91&type=chunk) - The company had no other significant related party transactions during the reporting period[92](index=92&type=chunk) [Significant Contracts and Their Performance](index=26&type=section&id=Significant%20Contracts%20and%20Their%20Performance) No trusteeship, contracting, leasing, or other major contracts occurred, but significant joint liability guarantees to subsidiaries totaled 870 million yuan, or 12.87% of net assets - The company had no trusteeship, contracting, or leasing situations during the reporting period[93](index=93&type=chunk)[94](index=94&type=chunk)[95](index=95&type=chunk) 2025 Semi-Annual Company's Significant Guarantees to Subsidiaries | Name of Guaranteed Party | Guarantee Limit (10,000 yuan) | Actual Guarantee Amount (10,000 yuan) | Guarantee Type | Fulfilled | | :--- | :--- | :--- | :--- | :--- | | Tumor Hospital | 10,000 | 10,000 | Joint and several liability guarantee | Yes | | Kekai Pharmaceutical | 20,000 | 20,000 | Joint and several liability guarantee | No | | Dadong Pharmaceutical | 5,000 | 5,000 | Joint and several liability guarantee | Yes | | Xinbang Pharmaceutical | 5,000 | 5,000 | Joint and several liability guarantee | Yes | | Tumor Hospital | 10,000 | 10,000 | Joint and several liability guarantee | No | | Tongde Pharmaceutical | 8,000 | 8,000 | Joint and several liability guarantee | No | | Tongde Pharmaceutical | 20,000 | 20,000 | Joint and several liability guarantee | No | | Kekai Pharmaceutical | 3,000 | 3,000 | Joint and several liability guarantee | Yes | | Tongde Pharmaceutical | 4,000 | 4,000 | Joint and several liability guarantee | No | | Tumor Hospital | 5,000 | 5,000 | Joint and several liability guarantee | No | | Dadong Pharmaceutical | 5,000 | 5,000 | Joint and several liability guarantee | No | | Xinbang Pharmaceutical | 5,000 | 5,000 | Joint and several liability guarantee | No | | Tongde Pharmaceutical | 10,000 | 10,000 | Joint and several liability guarantee | No | 2025 Semi-Annual Company's Total Guarantees | Indicator | Amount (10,000 yuan) | | :--- | :--- | | **Total Approved Guarantee Limit During Reporting Period** | 170,000 | | **Total Actual Guarantees Issued During Reporting Period** | 29,000 | | **Total Approved Guarantee Limit at End of Reporting Period** | 170,000 | | **Total Actual Guarantee Balance at End of Reporting Period** | 87,000 | | **Proportion of Total Actual Guarantees to Company's Net Assets** | **12.87%** | | **Balance of Guarantees Provided for Shareholders, Actual Controllers, and Related Parties** | 0 | | **Balance of Debt Guarantees Provided Directly or Indirectly for Guaranteed Parties with Debt-to-Asset Ratio Exceeding 70%** | 0 | | **Amount of Guarantees Exceeding 50% of Net Assets** | 0 | | **Total of the Above Three Guarantee Amounts** | 0 | - The company had no entrusted wealth management or other significant contracts during the reporting period[101](index=101&type=chunk)[102](index=102&type=chunk) [Explanation of Other Significant Matters](index=30&type=section&id=Explanation%20of%20Other%20Significant%20Matters) No other significant matters required explanation during the reporting period - The company had no other significant matters requiring explanation during the reporting period[103](index=103&type=chunk) [Significant Matters of Company Subsidiaries](index=30&type=section&id=Significant%20Matters%20of%20Company%20Subsidiaries) On March 3, 2025, subsidiary Kekai Pharmaceutical received notice of a unit bribery case from the Kaiyang County People's Court - On March 3, 2025, the company's controlled subsidiary, Kekai Pharmaceutical, received notification from the Kaiyang County People's Court of Guizhou Province regarding the acceptance of a case concerning unit bribery[105](index=105&type=chunk) Section 6 Share Changes and Shareholder Information This section details changes in the company's share capital, restricted shares, and provides an overview of shareholder structure and major holdings [Share Change Status](index=32&type=section&id=Share%20Change%20Status) Restricted shares decreased by 75,513,158, with an equal increase in unrestricted shares, maintaining total share capital due to executive lock-up release 2025 Semi-Annual Share Change Status | Share Category | Number Before This Change (shares) | Increase/Decrease in This Change (shares) | Number After This Change (shares) | | :--- | :--- | :--- | :--- | | **I. Restricted Shares** | 91,546,792 | -75,513,158 | 16,033,634 | | **II. Unrestricted Shares** | 1,852,305,076 | 75,513,158 | 1,927,818,234 | | **III. Total Shares** | 1,943,851,868 | 0 | 1,943,851,868 | - The share change was primarily due to the lifting of restrictions on executive lock-up shares[110](index=110&type=chunk) [Restricted Share Change Status](index=33&type=section&id=Restricted%20Share%20Change%20Status) An Huailue's 73,543,933 executive lock-up shares were released, reducing total restricted shares to 16,033,634, with other executive holdings unchanged 2025 Semi-Annual Restricted Share Change Status | Shareholder Name | Restricted Shares at Period-Beginning | Shares Released from Restriction in Current Period | Restricted Shares at Period-End | Reason for Restriction | | :--- | :--- | :--- | :--- | :--- | | An Ji | 15,088,796 | 0 | 15,088,796 | Executive lock-up shares | | An Huailue | 73,543,933 | 73,543,933 | 0 | Executive (departed) lock-up shares | | Kong Lingzhong | 567,525 | 0 | 567,525 | Executive lock-up shares | | Ding Yi | 112,038 | 0 | 112,038 | Executive lock-up shares | | Chen Jianping | 71,400 | 0 | 71,400 | Executive lock-up shares | | Huang Yongjia | 11,325 | 0 | 11,325 | Executive lock-up shares | | Zhang Jieqing | 106,425 | 0 | 106,425 | Executive lock-up shares | | Chen Chuan | 5,400 | 0 | 5,400 | Executive lock-up shares | | Lu Yafang | 6,600 | 0 | 6,600 | Executive lock-up shares | | Xiao Yaya | 64,125 | 0 | 64,125 | Executive lock-up shares | | Yang Pei | 452,125 | 0 | 452,125 | Executive (departed) lock-up shares | | Gao Wenlin | 1,517,100 | 0 | 1,517,100 | Executive (departed) lock-up shares | | **Total** | **91,546,792** | **73,543,933** | **16,033,634** | | [Securities Issuance and Listing Status](index=34&type=section&id=Securities%20Issuance%20and%20Listing%20Status) The company had no securities issuance or listing activities during the reporting period - The company had no securities issuance or listing activities during the reporting period[112](index=112&type=chunk) [Company Shareholder Count and Shareholding Status](index=34&type=section&id=Company%20Shareholder%20Count%20and%20Shareholding%20Status) The company had 66,696 common shareholders, with Guizhou Jinyu and Harbin Yuxi as top holders, some shares pledged/frozen, and 2.44% held in the repurchase account - At the end of the reporting period, the total number of common shareholders was **66,696**[111](index=111&type=chunk) 2025 Semi-Annual End Top 10 Shareholders' Shareholding Status | Shareholder Name | Shareholder Nature | Shareholding Ratio | Shares Held at Period-End | Restricted Shares Held | Unrestricted Shares Held | Share Status | Pledged, Frozen Shares | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Guizhou Jinyu Industrial Investment Partnership (Limited Partnership) | Domestic Non-State-Owned Legal Person | **18.52%** | 360,000,000 | 0 | 360,000,000 | Pledged | 33,000,000 | | Harbin Yuxi Venture Capital Co., Ltd | Domestic Non-State-Owned Legal Person | **18.46%** | 358,764,349 | 0 | 358,764,349 | Pledged/Frozen | 358,764,349 | | An Huailue | Domestic Natural Person | **5.04%** | 98,058,578 | 0 | 98,058,578 | Frozen | 9,000,000 | | Hong Kong Securities Clearing Company Limited | Overseas Legal Person | **1.12%** | 21,861,930 | 0 | 21,861,930 | Not applicable | 0 | | An Ji | Domestic Natural Person | **1.03%** | 20,118,395 | 15,088,796 | 5,029,599 | Not applicable | 0 | | UCPHARM COMPANY LIMITED | Overseas Legal Person | **0.99%** | 19,179,481 | 0 | 19,179,481 | Not applicable | 0 | | Zhang Guisu | Domestic Natural Person | **0.92%** | 17,953,614 | 0 | 17,953,614 | Not applicable | 0 | | Gao Ling | Domestic Natural Person | **0.57%** | 11,054,496 | 0 | 11,054,496 | Not applicable | 0 | | China Merchants Bank Co., Ltd. - Southern CSI 1000 ETF | Other | **0.56%** | 10,841,900 | 0 | 10,841,900 | Not applicable | 0 | | Gao Yuan | Domestic Natural Person | **0.48%** | 9,292,900 | 0 | 9,292,900 | Not applicable | 0 | - Guizhou Jinyu Industrial Investment Partnership (Limited Partnership) and An Huailue, An Ji are parties acting in concert[113](index=113&type=chunk) - Guizhou Xinbang Pharmaceutical Co., Ltd.'s dedicated share repurchase account holds **47,445,540 shares**, representing a **2.44%** shareholding ratio[113](index=113&type=chunk) [Changes in Shareholdings of Directors, Supervisors, and Senior Management](index=35&type=section&id=Changes%20in%20Shareholdings%20of%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) No changes occurred in the shareholdings of the company's directors, supervisors, or senior management during the reporting period - The shareholdings of the company's directors, supervisors, and senior management remained unchanged during the reporting period, with details available in the 2024 annual report[114](index=114&type=chunk) [Changes in Controlling Shareholder or Actual Controller](index=36&type=section&id=Changes%20in%20Controlling%20Shareholder%20or%20Actual%20Controller) No changes occurred in the company's controlling shareholder or actual controller during the reporting period - The company's controlling shareholder did not change during the reporting period[115](index=115&type=chunk) - The company's actual controller did not change during the reporting period[115](index=115&type=chunk) Section 7 Bond-Related Matters This section confirms the absence of any bond-related activities or outstanding debt instruments for the reporting period [Bond-Related Matters](index=38&type=section&id=Bond-Related%20Matters) The company had no bond-related matters during the reporting period - The company had no bond-related matters during the reporting period[118](index=118&type=chunk) Section 8 Financial Report This section presents the company's unaudited semi-annual financial statements, including balance sheets, income statements, cash flow statements, and detailed notes on accounting policies and financial items [Audit Report](index=39&type=section&id=Audit%20Report) The company's semi-annual financial report was unaudited - The company's semi-annual financial report was unaudited[120](index=120&type=chunk) [Financial Statements](index=39&type=section&id=Financial%20Statements) This section presents the company's 2025 semi-annual consolidated and parent company financial statements, detailing financial position, operating results, and cash flows - Financial statements include the consolidated balance sheet, parent company balance sheet, consolidated income statement, parent company income statement, consolidated cash flow statement, parent company cash flow statement, consolidated statement of changes in owners' equity, and parent company statement of changes in owners' equity[121](index=121&type=chunk)[126](index=126&type=chunk)[129](index=129&type=chunk)[133](index=133&type=chunk)[135](index=135&type=chunk)[138](index=138&type=chunk)[140](index=140&type=chunk)[145](index=145&type=chunk) [Company Basic Information](index=60&type=section&id=Company%20Basic%20Information) The company, listed on the Shenzhen Stock Exchange, focuses on medical services, pharmaceutical distribution, and TCM manufacturing, with a registered capital of 1,943.85 million yuan and 42 consolidated subsidiaries - The company's industry is pharmaceutical manufacturing, with a business scope covering pharmaceutical production, traditional Chinese medicine extract production, food production, health consulting services, medical research, and experimental development[150](index=150&type=chunk) - The company's main products include Yixinshu Capsules, Maixuekang Capsules, Guanjiekebi Pills (exclusive product), other pharmaceuticals, traditional Chinese medicine decoction pieces, and health products, with medical services as its primary service[150](index=150&type=chunk) - The company's registered capital is **1,943.851868 million yuan**, with a total of **1,943.851868 million shares**, of which **16.033634 million shares** are restricted tradable shares and **1,927.818234 million shares** are unrestricted tradable shares[152](index=152&type=chunk)[159](index=159&type=chunk) - The company included **42 subsidiaries** in its consolidation scope this period, an increase of **1 subsidiary** from the previous period[160](index=160&type=chunk) [Basis of Financial Statement Preparation](index=62&type=section&id=Basis%20of%20Financial%20Statement%20Preparation) Financial statements are prepared under Chinese accounting standards, using the accrual basis and historical cost, with fair value for equity investments, and a going concern assessment - Financial statements are prepared in accordance with the "Enterprise Accounting Standards" issued by the Ministry of Finance and "Rules for the Preparation of Information Disclosure by Companies Issuing Securities to the Public No. 15 - General Provisions for Financial Reports (Revised in 2023)" by the China Securities Regulatory Commission[162](index=162&type=chunk) - The company's accounting is based on the accrual method, and except for other equity instrument investments measured at fair value, these financial statements are measured at historical cost[164](index=164&type=chunk) - The company evaluated its ability to continue as a going concern for 12 months from the end of the reporting period and found no matters or circumstances that would cast significant doubt on its ability to continue as a going concern[163](index=163&type=chunk) [Significant Accounting Policies and Estimates](index=63&type=section&id=Significant%20Accounting%20Policies%20and%20Estimates) This section details significant accounting policies and estimates for business combinations, financial instruments, assets, revenue, and other areas, ensuring financial report standardization - The company adheres to enterprise accounting standards, accurately and completely reflecting the company's financial position, operating results, cash flows, and other relevant information for the reporting period[166](index=166&type=chunk) - The accounting period is from January 1 to December 31 of the Gregorian calendar, with this reporting period being from January 1, 2025, to June 30, 2025[167](index=167&type=chunk) - Detailed explanations are provided for accounting treatments of business combinations under common control and non-common control, as well as criteria for control judgment and methods for preparing consolidated financial statements[172](index=172&type=chunk)[174](index=174&type=chunk)[179](index=179&type=chunk)[180](index=180&type=chunk) - Classification, recognition, and measurement of financial instruments are covered, including financial assets and liabilities measured at amortized cost, at fair value through other comprehensive income, and at fair value through profit or loss[197](index=197&type=chunk)[198](index=198&type=chunk)[199](index=199&type=chunk)[200](index=200&type=chunk)[203](index=203&type=chunk)[204](index=204&type=chunk)[205](index=205&type=chunk) - Revenue recognition principles state that revenue is recognized when the customer obtains control of the related goods or services, with specific recognition methods tailored to business types (pharmaceutical manufacturing, pharmaceutical distribution, medical services)[295](index=295&type=chunk)[297](index=297&type=chunk) [Taxation](index=100&type=section&id=Taxation) The company and its subsidiaries benefit from various tax incentives, including reduced corporate income tax, VAT exemptions for medical services and certain drugs, and employment-related deductions Main Tax Categories and Rates | Tax Category | Tax Base | Tax Rate | | :--- | :--- | :--- | | **Value-Added Tax (VAT)** | Domestic sales; provision of processing, repair, and maintenance services; provision of tangible movable property leasing services | **13%** | | **Value-Added Tax (VAT)** | Real estate leasing services, sales of real estate, transfer of land use rights, sales of traditional Chinese medicine decoction pieces | **9%** | | **Value-Added Tax (VAT)** | Other taxable sales and service activities | **6%** | | **Value-Added Tax (VAT)** | Simplified tax calculation method | **5%, 3%, 1%** | | **Urban Maintenance and Construction Tax** | Actual paid turnover tax amount | **5%, 7%** | | **Corporate Income Tax** | Taxable income | **15%, 20%, 25%** | | **Education Surcharge** | Actual paid turnover tax amount | **3% (statutory), 2% (local)** | - The parent company and several subsidiaries enjoy a **15%** preferential corporate income tax rate for Western Development enterprises[102](index=102&type=chunk) - Guizhou Tongde Pharmaceutical Co., Ltd. enjoys corporate income tax exemption for income from initial processing of medicinal plants (traditional Chinese medicine decoction pieces)[102](index=102&type=chunk) - Several subsidiaries qualify for small and micro enterprise corporate income tax preferential policies, calculating taxable income at **25%** and paying corporate income tax at a **20%** rate[102](index=102&type=chunk) - Medical services provided by the company's hospitals are exempt from business tax and value-added tax[102](index=102&type=chunk)[103](index=103&type=chunk) - Small-scale VAT taxpayers with taxable sales revenue subject to a **3%** collection rate are subject to VAT at a **1%** collection rate[103](index=103&type=chunk) - Corporate income tax for enterprises employing disabled individuals can be additionally deducted by **100%** of the wages paid to disabled employees[103](index=103&type=chunk) - Contraceptive drugs and devices are exempt from VAT, while anti-cancer drugs and rare disease drugs can opt for a simplified method to calculate and pay VAT at a **3%** collection rate[103](index=103&type=chunk)[104](index=104&type=chunk) [Notes to Consolidated Financial Statement Items](index=104&type=section&id=Notes%20to%20Consolidated%20Financial%20Statement%20Items) This section provides detailed notes for all consolidated financial statement items, including assets, liabilities, equity, income, and expenses, with period-end balances, changes, and explanations 2025 Semi-Annual End Restricted Cash and Cash Equivalents | Item | Period-End Balance (yuan) | Period-Beginning Balance (yuan) | | :--- | :--- | :--- | | **Bank Acceptance Bill Deposits** | 40,580,545.03 | 82,792,572.56 | | **Frozen Cash and Cash Equivalents** | 966,417.01 | 0 | | **POS Machine Deposits** | 2,500.00 | 2,500.00 | | **Total** | **41,549,462.04** | **82,795,072.56** | - At the end of the reporting period, the company's goodwill book value was **603,749,295.25 yuan**, primarily arising from the acquisition of asset groups of Guizhou Kekai Pharmaceutical Co., Ltd., Guizhou Shengyuan Pharmaceutical Co., Ltd., Guizhou Guangzheng Pharmaceutical Sales Co., Ltd., and Guizhou Dadong Pharmaceutical Co., Ltd[130](index=130&type=chunk)[131](index=131&type=chunk) - The company fulfilled its performance commitments during the performance commitment period, and Zhongtai Biochemical Co., Ltd. and Kangyong Biotechnology Co., Ltd. were disposed of externally in June 2020, completing the disposal of goodwill formed from non-common control acquisitions[132](index=132&type=chunk) - During the reporting period, the company's operating revenue was **2,845,025,271.68 yuan**, and operating cost was **2,353,105,700.26 yuan**[144](index=144&type=chunk) - Net cash flow from operating activities was **227,425,647.80 yuan**, net cash flow from investing activities was **-44,856,072.31 yuan**, and net cash flow from financing activities was **-158,311,791.74 yuan**[137](index=137&type=chunk)[152](index=152&type=chunk) [Research and Development Expenses](index=156&type=section&id=Research%20and%20Development%20Expenses) All R&D expenditures, totaling 3.009 million yuan, were expensed during the period, covering salaries, office, depreciation, materials, and trial costs 2025 Semi-Annual R&D Expense Composition | Item | Amount Incurred in Current Period (yuan) | Amount Incurred in Prior Period (yuan) | | :--- | :--- | :--- | | **Salaries and Benefits** | 1,166,402.19 | 472,227.59 | | **Office and Travel Expenses** | 108,544.85 | 163,842.85 | | **Depreciation and Amortization** | 174,572.30 | 33,920.51 | | **Direct Materials** | 360,269.08 | 625,981.34 | | **Trial Production Costs** | 183,866.83 | 8,654.16 | | **Other R&D Expenses** | 1,015,778.99 | 850,795.89 | | **Total** | **3,009,434.24** | **2,155,422.34** | | **Of which: Expensed R&D Expenditures** | 3,009,434.24 | 2,155,422.34 | - At the end of the current period, the proportion of intangible assets formed through internal R&D to the total intangible asset balance was **0.00%**[129](index=129&type=chunk) [Changes in Consolidation Scope](index=157&type=section&id=Changes%20in%20Consolidation%20Scope) The company added Guizhou Daohe Real Estate to its consolidation scope via establishment, with no non-common control, common control, or reverse acquisitions - Guizhou Daohe Real Estate Co., Ltd. was newly established this period, with control obtained on **June 23, 2025**[160](index=160&type=chunk) - The company did not undergo non-common control business combinations or common control business combinations during the reporting period[165](index=165&type=chunk)[169](index=169&type=chunk) - The company did not undergo reverse acquisitions during the reporting period[160](index=160&type=chunk) [Interests in Other Entities](index=160&type=section&id=Interests%20in%20Other%20Entities) The company holds interests in 42 subsidiaries across diverse sectors, including key entities like Guizhou Xinbang and Guizhou Kekai, and acquired 49% of Guizhou Yiziyuan, reducing minority interests - The company owns **42 subsidiaries**, including Guizhou Xinbang Pharmaceutical Co., Ltd., Guizhou Kekai Pharmaceutical Co., Ltd., and Guizhou Medical University Affiliated Cancer Hospital Co., Ltd., with business natures covering commercial, manufacturing, agricultural, hospital, and service sectors[161](index=161&type=chunk)[162](index=162&type=chunk)[163](index=163&type=chunk) - In May 2025, the company acquired a **49% equity stake** in Guizhou Yiziyuan Biotechnology Co., Ltd. for **0 yuan**, making it a wholly-owned subsidiary[165](index=165&type=chunk) 2025 Semi-Annual Impact of Equity Change on Minority Interests and Equity Attributable to Parent Company Owners | Item | Amount (yuan) | | :--- | :--- | | **Total Purchase Cost/Disposal Consideration** | 0.00 | | **Less: Share of Subsidiary Net Assets Calculated by Acquired/Disposed Equity Ratio** | 371,466.51 | | **Difference** | **-371,466.51** | | **Of which: Adjustment to Capital Reserve** | -371,466.51 | 2025 Semi-Annual Key Financial Information of Important Non-Wholly Owned Subsidiaries | Subsidiary Name | Minority Shareholding Ratio | Net Profit Attributable to Minority Shareholders in Current Period (yuan) | Dividends Declared to Minority Shareholders in Current Period (yuan) | Minority Interest Balance at Period-End (yuan) | | :--- | :--- | :--- | :--- | :--- | | Guizhou Tongde Pharmaceutical Co., Ltd | **49.00%** | 49,080,724.69 | 124,215,000.00 | 185,656,843.29 | | Guizhou Medical University Affiliated Cancer Hospital Co., Ltd | **22.09%** | 5,455,441.89 | 0 | 76,766,432.01 | | Guizhou Dadong Pharmaceutical Co., Ltd | **49.00%** | 1,366,652.87 | 6,370,000.00 | 27,113,727.12 | [Government Grants](index=168&type=section&id=Government%20Grants) Government grants totaling 1.659 million yuan were recognized in profit or loss, primarily as other income and financial expense offsets, with deferred grants being asset-related 2025 Semi-Annual Government Grants Recognized in Profit or Loss | Accounting Account | Amount Incurred in Current Period (yuan) | Amount Incurred in Prior Period (yuan) | Asset/Income Related | | :--- | :--- | :--- | :--- | | **Other Income** | 1,659,558.66 | 2,018,439.94 | Asset/Income Related | | **Financial Expenses** | -2,000,000.00 | -974,500.00 | Asset Related | 2025 Semi-Annual Government Grants in Deferred Income | Project | Period-Beginning Balance (yuan) | Amount Recognized in Other Income in Current Period (yuan) | Period-End Balance (yuan) | Reason for Formation | Asset/Income Related | | :--- | :--- | :--- | :--- | :--- | :--- | | Standardization Cultivation and Application Demonstration Project for 4 Medicinal Herbs: Pinellia, Polygonum multiflorum, Dipsacus, and Polygonum capitatum | 2,572,916.99 | 162,499.98 | 2,410,417.01 | | Asset Related | | Phase III Expansion Investment Project | 268,999.64 | 134,500.02 | 134,499.62 | | Asset Related | | GSP Technology Transformation Project | 970,333.65 | 34,166.65 | 936,167.00 | | Asset Related | | National Essential Medicine Raw Material Seedling (Salvia miltiorrhiza, Codonopsis pilosula, Polygonatum sibiricum, Polygonum multiflorum) Breeding Base (Guizhou) Planting Base Construction Project | 1,131,730.66 | 148,023.54 | 983,707.12 | | Asset Related | | Southwest Pharmaceutical Preparation National Local Joint Engineering Research Center (Guizhou) Innovation Capacity Building Project | 3,000,000.00 | 250,000.00 | 2,750,000.00 | | Asset Related | | Capsule Production Line Supporting Expansion Project | 49,999.64 | 25,000.02 | 24,999.62 | | Asset Related | | Hospital Nucleic Acid Laboratory Construction Project | 1,026,666.72 | 109,999.98 | 916,666.74 | | Asset Related | | Annual Output of 3000T Traditional Chinese Medicine Decoction Piece Production Workshop Renovation and Expansion Project | 2,371,428.54 | 42,857.16 | 2,328,571.38 | | Asset Related | | **Total** | **19,515,977.91** | **907,047.35** | **18,608,930.56** | | | [Risks Related to Financial Instruments](index=169&type=section&id=Risks%20Related%20to%20Financial%20Instruments) The company manages credit, liquidity, and market risks through various policies, monitoring, and controls, with no significant foreign exchange risk and controllable interest rate risk - The company faces credit risk, liquidity risk, and market risk (including exchange rate risk, interest rate risk, and other price risks)[169](index=169&type=chunk) - Credit risk management measures include transacting only with creditworthy counterparties, assessing customer creditworthiness and setting credit terms, continuously monitoring notes receivable, accounts receivable balances and recovery, and depositing cash and cash equivalents with highly reputable financial institutions[169](index=169&type=chunk)[170](index=170&type=chunk) 2025 Semi-Annual End Financial Asset Credit Risk Exposure | Item | Period-End Book Balance (yuan) | Impairment Provision (yuan) | | :--- | :--- | :--- | | **Notes Receivable** | 78,419,617.46 | 0 | | **Receivables Financing** | 89,000,541.25 | 0 | | **Accounts Receivable** | 2,852,878,117.72 | 371,756,617.74 | | **Other Receivables** | 424,297,829.52 | 103,420,748.49 | | **Total** | **3,444,596,105.95** | **475,177,366.23** | - Liquidity risk is centrally controlled by the finance department, monitoring cash balances, marketable securities, and 12-month cash flow forecasts to ensure sufficient funds[170](index=170&type=chunk) - Exchange rate risk primarily arises from financial assets and liabilities denominated in Euros, but the company's current operating activities are all within China, posing no significant foreign exchange risk[170](index=170&type=chunk) - Interest rate risk mainly originates from bank borrowings and bonds payable, with the company controlling risk by strictly managing interest rate levels and expanding financing channels[171](index=171&type=chunk) - Other price risks primarily stem from product price reductions due to bidding policies, which the company mitigates by achieving cost advantages through centralized procurement[171](index=171&type=chunk) [Fair Value Disclosure](index=172&type=section&id=Fair%20Value%20Disclosure) Period-end assets measured at fair value, primarily Level 3 equity investments and receivables financing, are valued at face amount or carrying cost due to market limitations 2025 Semi-Annual End Assets Measured at Fair Value | Item | Level 3 Fair Value Measurement (yuan) | Total (yuan) | | :--- | :--- | :--- | | **Other Equity Instrument Investments** | 327,465,156.74 | 327,465,156.74 | | **Receivables Financing** | 89,000,541.25 | 89,000,541.25 | | **Total Assets Continuously Measured at Fair Value** | **416,465,697.99** | **416,465,697.99** | | **Total Liabilities Continuously Measured at Fair Value** | **0.00** | **0.00** | - Receivables financing is recognized at its face amount for period-end fair value[172](index=172&type=chunk) - Other equity instrument investments are estimated at cost as the best estimate of fair value at period-end due to a lack of active market quotes and reliable measurement bases[172](index=172&type=chunk) [Related Parties and Related Party Transactions](index=173&type=section&id=Related%20Parties%20and%20Related%20Party%20Transactions) The company's controlling shareholder is Guizhou Jinyu, with An Ji as actual controller; related party transactions included pharmaceutical procurement and non-operating fund movements - The company's controlling shareholder is Guizhou Jinyu Industrial Investment Partnership (Limited Partnership), and the actual controller is An Ji[173](index=173&type=chunk) 2025 Semi-Annual Related Party Transactions for Purchase of Goods/Receipt of Services | Related Party Name | Related Transaction Content | Amount Incurred in Current Period (yuan) | Approved Transaction Limit (yuan) | | :--- | :--- | :--- | :--- | | Guizhou Guangzheng Pharmaceutical Co., Ltd | Purchase of pharmaceuticals | 657,295.07 | 3,600,000.00 | | Harbin Yuying Pharmaceutical Co., Ltd. and its subsidiaries | Purchase of pharmaceuticals | 5,148,634.24 | 14,000,000.00 | | Guizhou Huangguoshu Lishuang Pharmaceutical Co., Ltd | Purchase of pharmaceuticals | 452,553.98 | 1,300,000.0

募集资金管理制度 贵州信邦制药股份有限公司 募集资金管理制度 第一章 总则 第一条 为了规范贵州信邦制药股份有限公司（以下简称"公 司"）募集资金的管理，提高募集资金使用效率，根据《中华人民共 和国公司法》、《中华人民共和国证券法》、《上市公司证券发行注 册管理办法》、《首次公开发行股票注册管理办法》、《上市公司监 管指引第2号——上市公司募集资金管理和使用的监管要求》、《深 圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运 作》等法律、法规、规范性文件的有关规定，结合公司实际情况，制 定本制度。 第二条 本制度所称募集资金是指公司通过公开发行股票或者 其他具有股权性质的证券，向投资者募集并用于特定用途的资金，不 包括公司为实施股权激励计划募集的资金。 本制度所称超募资金是指实际募集资金净额超过计划募集资金 金额的部分。 第三条 公司应当审慎使用募集资金，保证募集资金的使用与招 股说明书或者募集说明书的承诺相一致，不得随意改变募集资金的投 向。 公司应当真实、准确、完整地披露募集资金的实际使用情况，并 在年度审计的同时聘请会计师事务所对募集资金存放与使用情况进 1 募集资金管理制度 行鉴证。 第四 ...

年报信息披露重大差错责任追究制度 贵州信邦制药股份有限公司 年报信息披露重大差错责任追究制度 第一章 总则 第一条 为了提高贵州信邦制药股份有限公司（以下简称"公 司"）的规范运作水平，增强信息披露的真实性、准确性、完整性和 及时性，加大对年报信息披露责任人的问责力度，提高年报信息披露 的质量和透明度，根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人 民共和国会计法》（以下简称"《会计法》"）、《上市公司信息披露管理 办法》、《上市公司治理准则》和《深圳证券交易所股票上市规则》等 法律法规、规范性文件及《贵州信邦制药股份有限公司章程》（以下 简称"《公司章程》"）、公司《信息披露管理制度》的有关规定，结 合公司实际情况，特制定本制度。 第二条 公司有关人员应当严格执行《企业会计准则》及相关法 律法规的规定，严格遵守公司与财务报告相关的内部控制制度，确保 财务报告真实、公允地反映公司的财务状况、经营成果和现金流量。 公司有关人员不得干扰、阻碍审计机构及相关注册会计师独立、客观 地进行年报审计工作。 第三条 公司董事、高级管理人员以及与年报信息 ...

独立董事工作制度 贵州信邦制药股份有限公司 独立董事工作制度 独立董事工作制度 第一章 总则 第一条 为进一步完善贵州信邦制药股份有限公司（以下简称 "公司"）法人治理结构，促进公司规范运作，保障公司独立董事依 法独立行使职权，根据《中华人民共和国公司法》、《中华人民共和国 证券法》、《上市公司治理准则》、《国务院办公厅关于上市公司独立董 事制度改革的意见》、《上市公司独立董事管理办法》、《深圳证券交易 所股票上市规则》等法律、行政法规、规范性文件以及《贵州信邦制 药股份有限公司章程》（以下简称"《公司章程》"）的有关规定， 制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与 公司及其主要股东、实际控制人不存在直接或者间接利害关系，或者 其他可能影响其进行独立客观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制 人等单位或个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当 按照法律、行政法规、中国证券监督管理委员会（以下简称"中国证 监会"）规定、深圳证券交易所业务规则和《公司章程》的规定，认 真履行职责，在董事会中发挥参与决策、监督制衡、专业 ...

信息披露管理制度 贵州信邦制药股份有限公司 信息披露管理制度 第一章 总则 第一条 为加强对贵州信邦制药股份有限公司 （以下简称"公 司"）及子公司的信息披露行为，加强信息披露事务管理，保护投资 者合法权益，根据《中华人民共和国公司法》 、《中华人民共和国证 券法》(以下简称"《证券法》") 、《上市公司信息披露管理办法》、 《深圳证券交易所股票上市规则》 、《深圳证券交易所上市公司自律 监管指引第 5 号——信息披露事务管理》等相关法律、法规、规范性 文件及《公司章程》的有关规定，特制定本制度。 第二条 本制度所称"信息披露义务人"，是指公司及其董事、 高级管理人员、股东、实际控制人，收购人，重大资产重组、再融资、 重大交易有关各方等自然人、单位及其相关人员，破产管理人及其成 员，以及法律、行政法规和中国证监会规定的其他承担信息披露义务 的主体。 第三条 本制度所称"信息"，指根据法律、法规和规范性文 件及深圳证券交易所其他相关规定应当披露的，对公司股票及其衍 生品种交易价格可能或者已经产生较大影响的信息。 第四条 本制度所称"披露"，是指信息披露义务人按法律、 法规和规范性文件及深圳证券交易所其他相关规定 ...

董事、高级管理人员薪酬及绩效考核管理制度 贵州信邦制药股份有限公司 董事、高级管理人员薪酬及绩效考核管理制度 第一章 总则 第一条 为强化资产经营责任，建立和完善现代企业董事、高级 管理人员的激励和约束机制，树立个人薪酬与公司业绩挂钩的目标与 价值导向，提升公司资产经营效益和管理水平，根据《中华人民共和 国公司法》、《上市公司治理准则》、《贵州信邦制药股份有限公司章程》 的规定，结合公司实际，特制定本管理制度。 第二条 本制度适用对象为： （一）在公司担任董事的人员（包括董事长，但不包括股东单位 任职的董事）； （二）公司高级管理人员，包括总经理、董事会秘书、副总经理、 财务总监以及其他经公司董事会批准列入高级管理人员范围的人员； （三）公司独立董事。 董事、高级管理人员薪酬及绩效考核管理制度 第三条 公司董事、高级管理人员的薪酬以公司经营规模和绩效 为基础，根据公司经营计划和分管工作的职责、目标，进行综合考核 确定。 第四条 公司董事、高级管理人员薪酬及绩效考核原则： （一）坚持按劳分配与责、权、利相结合的原则； （二）绩效优先，体现与公司收益分享、风险共担的价值理念； （三）总体薪酬水平兼顾内外部公平，并 ...